COMPANY SHOWCASE: GRAYBUG

Citation: O’Rourke M et al, “Company Showcase: Graybug”. ONdrugDelivery Magazine, Issue 54 (Jan 2015), pp 24-25.

GRAYBUG OVERVIEW

GrayBug is advancing ophthalmic therapeutics through a continuum of polymer-based drug delivery platforms and innovative products offering sustained competitive advantage. Its technologies include proprietary biodegradable drug-loaded nanoparticles, microparticles and injectable implants providing extended release of small to large molecules for intraocular applications to treat ocular diseases.

The company’s business objective is to build and implement two synergistic development strategies in major global ocular disease segments:

1) Proprietary Product Development Programs with lead compounds in neovascular diseases such as age-related macular degeneration (AMD) and diabetic retinopathy, and glaucoma. Worldwide markets for AMD and glaucoma currently exceed US$9 billion with significant market need existing for product enhancements and innovation through extended release drug delivery.

2) Proprietary Polymer-Based Technologies that deliver a wide range of drugs, including small molecules, peptides, proteins, aptamers, and other biologics.

VALUE PROPOSITION

“GrayBug’s controlledrelease technologies may reduce dosing frequencies to only 2-3 times per year, which is expected to improve patient compliance and drug efficacy…”

  • Unique continuum of drug delivery platforms – small to large molecule spectrum including proteins – micro and nanoparticles, injectable implants
  • Customised development for target drug
  • Proven success rate with multiple molecules tested to date
  • Significant reduction of inflammation associated with conventional particles, including PLGA microparticles
  • Efficacy in multiple animal models for multiple drugs in the pipeline
  • Published preclinical data – proof of concept for platform technology.

PROOF-OF-CONCEPT

Proof of concept has been demonstrated in animals for all products in the pipeline (Figure 1) including GrayBug’s AMD and glaucoma drug candidates. The company’s proprietary controlled-release drug delivery systems can be tailored to meet performance requirements of duration and rate of drug release. GrayBug possesses the technical expertise, experience, and capacity to collaborate with select partners in areas of mutual interest.

Our world-class team and advisors have over 100 peer-reviewed publications on the long-term, controlled delivery of biologics.

Figure 1: Development pipeline showing milestone achievements.

GRAYBUG’S TECHNOLOGY

GrayBug’s proprietary technologies allow customisable sustained release of all therapeutic classes, when delivered intraocularly (Figure 2). GrayBug’s controlled-release technologies may reduce dosing frequencies to only 2-3 times per year, which is expected to improve patient compliance and drug efficacy.

“Our world-class team and advisors have over 80 peer-reviewed publications on the long-term, controlled delivery of biologics…”

Pipeline products include GB-102, which is a single drug agent that inhibits multiple pathogenic angiogenesis signals, and innovative glaucoma therapies GB-201-204 for the controlled-release of intraocular pressure-lowering drugs and for long-term protection of the optic nerves to prevent blindness.

Figure 2: GrayBug controlled-release drug delivery.

SUMMARY

  • GrayBug offers major product development opportunities for the extended and controlled release of small and large molecules including proteins
  • Strong intellectual property position. Two issued US patents, and US and international patent application families protecting two drug delivery platform technologies through 2031
  • Proprietary preclinical product development programs in AMD and glaucoma
  • Strong and experienced management team in ocular drug delivery development and commercialisation, and world-class leaders in development of long-lasting protein delivery systems
  • Awarded four Small Business Innovation Research (SBIR) grants GrayBug welcomes invitations from interested parties to enter discussions about significant business development and partnership opportunities.

Comment on this article

Top